tbuckley/cabot-search huggingface dataset:
Abstract 12397: Obesity and the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis
Authors: Christopher X Wong, Michelle T Sun, Rajiv Mahajan, Rajeev Pathak, Darryl P Leong, Dennis H Lau, Kurt C Roberts-Thomson, Prashanthan Sanders
Journal: Circulation (2012)

Background: A number of studies have suggested that obesity is an emerging risk factor for atrial fibrillation (AF). Given the dual epidemics of obesity and AF, public health strategies to combat o...
Hormonal treatment of metastatic endometrial stromal sarcoma
Authors: K. Y. Terada, J. Davis, J. Kitayama, D. Shimizu
Journal: Journal of Clinical Oncology (2009)

e16576 Background: Endometrial stromal sarcomas (ESS) traditionally have been classified as low grade or high grade based on mitotic activity and histologic appearance. High-grade tumors are currently referred to as undifferentiated uterine sarcomas and are not included in this series. ESS are known to have high expression of estrogen and progesterone receptors. This is a retrospective study of patients with metastatic ESS treated with hormonal therapy. Methods: Following approval by the institutional review board all patients diagnosed with ESS from 1987–2007 were identified. Clinical and demographic information were abstracted from the charts and all histologic materials were re-reviewed. Estrogen and progesterone receptor testing was performed utilizing mouse monoclonal antibodies and the Cell Analysis Systems 200 Image analyzer. Survival was calculated using the Kaplan-Meier method and comparisons utilized the log rank test. Results: Thirteen patients with ESS were identified during this period. Seven had disease confined to the uterus. Six had extrauterine disease; 5 patients presented with metastases and 1 patient presented with a pelvic recurrence 20 years following a hysterectomy. All underwent surgical resection except for 1 patient that declined surgery. All 6 patients with metastases had tumors that tested positive for estrogen and progesterone receptors; all were treated with megestrol acetate initially for a period of 1–4 years. Two patients were then changed to maintenance with medroxyprogesterone acetate. Three patients with persistent disease were changed to aromatase inhibitors; 1 to letrozole and 2 to anastrazole. One of these patients has had a complete response and 2 have had stable disease. One patient has been lost to follow-up. Follow-up for the 6 patients was 2–22 years; no known patients died of their disease. Actuarial 2- and 5-year survivals were 80% and 65%, respectively. There was no significant difference in survival between patients with metastases and without metastases. Conclusions: ESS tumors are relatively uncommon and there is an absence of studies to guide treatment of patients with metastases. This experience indicates that these tumors respond well to hormonal manipulation. Treatment with progestins or aromatase inhibitors may result in remission or stable disease. No significant financial relationships to disclose.
Put patients first and give the money back
Authors: Fiona Godlee
Journal: BMJ (2015)

I've been treated so wonderfully that you wouldn't believe it."Although his cancer returned, his satisfaction with the promptness of his care suggests that his GP used the fast track referral pathway for suspected cancer.And we now have evidence that this pathway works.Henrik Møller and colleagues found better outcomes among patients whose doctors made more use of fast track referral (doi:10.1136/bmj.h5102).On this basis, failing to fast track patients with suspected cancer looks like poor practice.How then would secondary care services cope if all GPs made full use of fast track referral, especially at the new lower referral thresholds recommended by NICE in its recent guidance (doi:10.1136/bmj.h3044)?Given the dire financial forecast for England's NHS (doi:10.1136/bmj.h5430),few can doubt that more money is urgently needed.Without it, care of patients will suffer, and the current crisis could be used to erode the public's faith in an NHS that is free at the point of care.But what of the longer term?Shouldn't healthcare learn to live within its means?
Chemoradiotherapy for unresectable locally advanced pancreatic cancer: A pilot study
Authors: C. Milandri, R. Polico, A. Gardini, A. Passardi, A. Romeo, A. Zaccaroni, P. Rosetti, D. Garcea
Journal: Journal of Clinical Oncology (2008)

15630 Background: In pancreatic cancer, surgical treatment at the time of diagnosis is only feasible in 10–20% of patients. We evaluated a chemo-radiotherapy regimen in an attempt to improve resecability. Methods: From August 2004 to November 2007, twenty-seven patients with non resectable, locally advanced pancreatic cancer were prospectively enrolled onto an institutional pilot trial. All patients received chemo-radiotherapy, the former consisting of the GEMOX regimen: Gemcitabine (GEM) 1000 mg/m2 on day 1 and Oxaliplatin (OX) 100 mg/m2 on day 2 every two weeks for 3–4 cycles. Radiotherapy (split-course accelerated hyperfractionation using dynamic intensity modulation and ‘sliding-windows’ dose delivery techniques, 25 Gy in 5 fractions) was administered to all patients 15 days after the 3rd-4th chemotherapy cycle. Patients then received a further 3–4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery. Unresectable responders received 4 more cycles of GEMOX and further radiotherapy (total of 15 Gy in 3 sessions). Results: Patients received 6–12 cycles of GEMOX. Median duration of treatment was 161 days (range: 76–175). After chemo-radiotherapy, 10/27 (37%) patients obtained a partial tumor response, 10 showed stable disease, 6 progressed, and 1 was not evaluable. Five patients are currently being evaluated for surgery. Another 5 who showed a reduction in vascular infiltration underwent surgical laparotomy: 3 radical pancreatic resection (1 splenopancreatectomy and 2 total pancreatectomy), and 2 explorative laparotomy. R0 margin was achieved in 2 cases submitted to pancreatic resection, while the remaining patient was R1. One patient is still alive without signs of recurrence 2 years after radical pancreatectomy, while the other 2 died from distant metastases 6 and 7 months after the surgical procedure. GEMOX toxicity was similar to that reported in the literature (Louvet et al., J Clin Oncol, 2005). Radiotherapy was well tolerated. Conclusions: Our results show the potential efficacy of the chemo-radiotherapy association. A phase II study is now being planned. No significant financial relationships to disclose.
Surgical Indications and Results for Congenital Cardiac Anomalies associated with Left to Right Shunt and Severe Pulmonary Hypertension
Authors: Akira Shohtsu, Shigeyuki Takeuchi, Tadashi Inoue
Journal: Circulation (1976)

Prior to 1970, 35 patients of VSD with Pp/Ps of 0.8 or more were subjected to primary closure of the defect, resulting in 11 operative deaths. Since 1971, however, the surgical results have been much improved and 29 such patients were operated on without death. It has been considered the optimal time of elective closure of VSD with severe pulmonary hypertension is at the age of 1 to 3 years, however, if decrease in apical diastolic rumble and heart size are found, earlier operation less than one year of age is to be scheduled. surgical indications and results of PDA, PDA with VSD and ASD associated with severe pulmonary hypertension were also discussed.
Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) mRNA expression in patients with metastatic gastric cancer receiving first-line chemotherapy
Authors: C. Pauligk, R. Wirtz, K. Steinmetz, J. T. Hartmann, N. Homann, R. D. Hofheinz, C. Petry, H. M. Altmannsberger, E. Jäger, S. Al-Batran
Journal: Journal of Clinical Oncology (2009)

4547 Background: In preclinical tumor models, VEGF and MMP-9 induced each other, resulting in the enhancement of tumor angiogenesis and the formation of metastases. This study evaluated MMP-9 and VEGF in patients (pts) with metastatic gastric cancer. Methods: Patient tumor samples from a phase III trial of the AIO were prospectively collected. VEGF and MMP-9 mRNA were isolated from paraffin embedded tissues using a new patented method based on nanotechnology. The expression was then assessed by qRT-PCR and by immunohistochemistry (IHC). Results: A total of 137 (training cohort 96; validation cohort 41) out of 220 pts enrolled were analyzed. In the training cohort, increased MMP-9 levels were strongly associated with increased VEGF expression, resistance to chemotherapy and shorter progression-free and overall survival. At the cut-off with the highest predictive value, the rate of disease progression as best response associated with elevated MMP9 expression was 50% (vs. 22.4%; Fisher's test p=.027) and median overall survival (OS) was 3.1 months (vs. 8.7 months, log rank p=.0000165). This prognostic value for survival was maintained when data were analyzed in the multivariate setting (relative hazard ratio for death 3.67, p=.00045) or were categorized according to the quartile (p=.004) or median (p=.024) distributions for MMP-9. VEGF showed a prognostic effect in pts with low MMP-9 expression, only. In the validation cohort, the prognostic value of increased MMP-9 expression could be confirmed at the best cut off derived from the training cohort, with the hazard ratio for death being 3.45 (p=.02). Interestingly, in the IHC, stromal but not tumoral MMP-9 protein expression predicted survival (log rank p=.033). Conclusions: Tumoral MMP-9 mRNA expression levels are the first validated molecular prognostic factor in metastatic gastric cancer. These results have implications for novel anti-protease/ anti-VEGF treatment strategies. [Table: see text]
Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.
Authors: R. K. Stuart, F. Ravandi Kashani, L. D. Cripe, M. B. Maris, M. A. Cooper, S. R. Dakhil, R. M. Stone, F. Turturro, J. A. Fox, G. Michelson
Journal: Journal of Clinical Oncology (2010)

6525 Background: Voreloxin, an anticancer quinolone derivative that inhibits topoisomerase II, has demonstrated clinical activity in ovarian cancer and acute myeloid leukemia (AML). Final results are reported from this phase II study (n = 113). Methods: Eligible patients had AML (WHO subtype, except APL) considered unlikely to benefit from standard induction therapy, with ≥ 1 adverse risk factor: age ≥ 70, secondary AML, intermediate (I) or unfavorable (U) cytogenetics, or PS = 2. Voreloxin was administered by short (≤ 10 min) IV infusion in 3 dosing schedules: A, weekly (qwk)×3 (days [d] 1, 8, 15) at 72 mg/m2 (n = 29); B, qwk×2 (d 1, 8) at 72 mg/m2 (n = 35); and C, twice weekly (biw)×1 (d 1, 4) at 72 (n = 29; C72) or 90 mg/m2 (n = 20; C90) for up to 4 cycles. Results: Median age was 74 years, most patients were male with an ECOG PS 0 or 1, and cytogenetics were I (46%) or U (42%) per 2010 NCCN guidelines. The overall remission rate (ORR = CR+CRp [complete remission + CR with incomplete platelet recovery]) across all doses and schedules was 34% (range, 25-41%) and 74% of CR were in first cycle. Reinduction resulted in CR(p) for 35% of those reinduced. By schedule, ORR was 41% for A, 29% for B, 38% for C72, and 25% for C90. No dose response was observed between C72 and C90. All-cause mortality rates were lowest in C72 (7% at 30 days, 17% at 60 days) compared with A, B, and C90. Median duration of remission (DR) was 10.7 months (mo) for A (median too early to evaluate [TETE] for B, C72, or C90). Median overall survival (OS) was 8.7 mo (A), 5.8 mo (B), 7.3 mo (C72, preliminary); C90 is TETE. One-year OS was 38% for A and TETE for other schedules. Across all schedules, the most common nonhematologic adverse events grade ≥ 3 were febrile neutropenia (49%) and infections: pneumonia (28%) and sepsis/bacteremia (28%). Overall safety profile was more acceptable for C72 than for A and appeared further improved over B. ORR was 30% for patients ≥ 75 years. Conclusions: Voreloxin induced durable remissions in 3 dosing schedules. Schedules B and C maintained activity and improved tolerability over A. Schedule C72 is appropriate for further development based on ORR, all-cause mortality, and safety profile. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sunesis Pharmaceuticals Sunesis Pharmaceuticals Sunesis Pharmaceuticals
Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins
Authors: AA Higazi, RH Upson, RL Cohen, J Manuppello, J Bognacki, J Henkin, KR McCrae, MZ Kounnas, DK Strickland, KT Preissner, J Lawler, DB Cines
Journal: Blood (1996)
Infusional topotecan with concurrent radiation followed by consolidation etoposide platinum and docetaxel for patients with high risk unresectable stage III non-small cell lung cancer (NSCLC)
Authors: S. Seung, B. K. Fisher, H. J. Ross
Journal: Journal of Clinical Oncology (2006)

17042 Background: Good PS patients (pts) with locally advanced NSCLC treated with concurrent chemoradiotherapy have a 20–40% 3 year survival. Treatment is arduous and poor PS or high risk pts often cannot complete a full course of treatment. The optimal combination of chemotherapy and radiation and the role of consolidation chemotherapy are unknown. Despite response rates exceeding 50%, most pts eventually progress with brain as the first site of relapse in up to 30%. Continuous infusion chemotherapy is better tolerated than intermittent chemotherapy combined with radiation and may improve outcome in other locally advanced aerodigestive malignancies, however it has not been studied extensively in NSCLC. Topotecan is active in NSCLC, can safely be combined with radiation, can be given by continuous infusion and penetrates the CNS making it an attractive study agent in locally advanced NSCLC. Methods: In this pilot study, 20 pts were treated with infusional topotecan 0.4 mg/m 2 /d with 3D conformal radiation to 63 Gy both delivered M-F for 7 weeks. Pts without progressive disease underwent consolidation chemotherapy with etoposide and platinum for one cycle to take advantage of upregulation of topoisomerase II by topotecan. Two cycles of docetaxel consolidation followed. Study endpoints include response, time to progression, survival, toxicity and development of CNS metastases. Results: All pts have completed induction chemoradiotherapy. 12/20 have completed consolidation. 17/20 pts had a PR and 1/20 SD after induction chemoradiation. 1 pt developed CNS metastases 228 days after study entry and is alive with disease at 541 days. 3 pts had pulmonary emboli. Therapy has been well tolerated with 1/20 grade 4 lymphopenia. Grade 3 hematologic toxicity was seen in 17/20 pts. Other grade 3 toxicities include esophagitis (3/20), esophageal stricture (2/20), pneumonitis (6/20), fatigue (6/20), weight loss (1/20). Conclusion: Continuous infusion topotecan with radiation is well tolerated and shows evidence of activity in the management of poor risk patients with unresectable stage III NSCLC. Survival data will be presented at the meeting. No significant financial relationships to disclose.
Haemoglobin (Hb) Levels and Quality of Life (Qol) in Patients (Pts) with Symptomatic Chemotherapy-Induced Anaemia (Cia): the Eaqua Study
Authors: G. Tonini, J. Mouysset, B. Freier, J. van den Bosch, C.B. Levaché, A. Bols, H.W. Tessen, L. Belton, C. Bohac, J. Terwey
Journal: Annals of Oncology (2014)
Abstract 192: Histological and Functional Assessment of Human Placental Stem Cells in an Induced Myocardial Infarction in Rats
Authors: Georges Makhoul, Yu-Ting Ma, Minh Duong, Ray C J Chiu, Renzo Cecere
Journal: Circulation Research (2012)

Purpose: Human bone marrow mesenchymal stem cells (hbmMSCs) have been studied extensively for myocardial regenerative therapy. However, such cells require invasive procreation and suffer from donor age-related declining quality. Recently, a more abundant resource of young MSCs has been isolated from an otherwise discarded organ: the human placenta mesenchymal stem cells (hpMSCs). In this study, we wanted to examine the survival, differentiation, and functionality of xenogeneic hpMSCs when implanted into an induced myocardial rat infarction. Methods: To inspect their stemness,hpMSCs underwent an In Vitro cardiac cell differentiation in a DMEM medium containing 5 Azacytidine. Additionally, hpMSCs were tested in a myocardial infarction animal model. Female Lewis rats (40 animals) underwent left coronary artery ligation. Animals were divided into 4 groups. Group 1 was injected with hpMSCs in the peri-infarct region. Groups 2 and 3 received hbmMSCs and In Vitro differentiated hbmMSCs into cardiomyocytes respectively. Cell free medium was injected in group 4. Echocardiography was performed at baseline, day 4, weeks 3, 6, and 9 after ligation. Myocardial tissues were harvested and studied immunohistochemically for specific muscular and cardiac markers (Actin and Troponin I) on weeks 6 and 10. Results: In Vitro differentiation into cardiomyocyte lineage was achieved with the hpMSCs. HpMSCs were detected within rat myocardium by week 6 after their implantation. These cells stained positively for Actin and Troponin I. Preliminary echocardiographic data show cardiac functional increase in group 1. Whether hpMSCs can provide a superior effect than hbmMSCs or differentiated hbmMSCs is being investigated. Conclusions: In Vitro studies indicated that the hpMSCs can be differentiated into cardiac cells. When implanted into the rat infarcted myocardium, hpMSCs survived and were able to differentiate into cardiomyocytes. These cells appeared to increase cardiac function in an induced myocardial infarction rat model. With the advantages of easy availability and young age, hpMSCs could be more suitable for myocardial regenerative therapy.
Hedgehog Blockade for Basal Cell Carcinoma
Authors: Albert Rübben, Ralf-Dieter Hilgers, Martin Leverkus
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Dual-focus versus conventional magnification endoscopy for the diagnosis of superficial squamous neoplasms in the pharynx and esophagus: a randomized trial
Authors: Kenichi Goda, Akira Dobashi, Noboru Yoshimura, Hiroyuki Aihara, Masayuki Kato, Kazuki Sumiyama, Hirobumi Toyoizumi, Tomohiro Kato, Hiroki Saijo, Masahiro Ikegami, Hisao Tajiri
Journal: Endoscopy (2016)

<b>Background and study aims:</b> Conventional magnification narrow-band imaging (CM-NBI) endoscopy has demonstrated high diagnostic accuracy for superficial squamous neoplasms in the pharynx and esophagus. This study aimed to evaluate the diagnostic utility of the newly developed dual-focus NBI (DF-NBI) compared with that of CM-NBI. <b>Patients and methods: </b>We recruited patients with squamous cell carcinoma (SCC) in the head and neck, or esophagus, or with a history of SCC. The primary endpoint of this prospective controlled non-inferiority trial was the sensitivity of DF-NBI and CM-NBI for detecting superficial carcinoma in the pharynx and esophagus. Secondary endpoints included other diagnostic values and the resolving power of each endoscope. Superficial carcinoma was defined as high grade dysplasia and SCC invading up to the submucosal layer. <b>Results: </b>The study included 93 patients. A total of 28 superficial carcinomas were detected in the pharynx and esophagus. The sensitivities of DF-NBI and CM-NBI for superficial carcinoma were 82 % and 71 %, respectively. The lower limit of the 90 % confidence interval for the difference between the sensitivities exceeded the non-inferiority threshold. The specificity and overall accuracy of DF-NBI vs. CM-NBI were 93 % vs. 90 % and 91 % vs. 86 %, respectively (both non-significant differences). The maximum resolving power of a conventional magnification endoscope was significantly higher than a dual-focus endoscope (7.2 µm vs. 11.6 µm: <i>P</i> < 0.001). <b>Conclusions: </b>The findings indicate the non-inferiority of DF-NBI versus CM-NBI in detecting superficial carcinoma in the pharynx and esophagus. DF-NBI appears to have a resolving power that, although significantly lower, is sufficient to achieve high diagnostic accuracy, comparable to that of CM-NBI. University Hospital Medical Information Network (UMIN, No. 000007585).
Abnormal Size Profiles of Soluble Macromolecules From Azo-Dye Liver Tumors&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Sam Sorof, Emily M. Young, Regina Z. McBride, Carol B. Coffey
Journal: JNCI Journal of the National Cancer Institute (1971)

In a search for aberrations associated with neoplasms resulting from chemical carcinogens, the soluble macromolecules of primary liver tumors were extensively resolved according to molecular size, and the resultant profiles were compared with those from normal and preneoplastic livers. Primary liver tumors were obtained from male rats after long-term ingestion of the liver azocarcinogen 3′-methyl-4-dimethylaminoazobenzene (3′-Me-DAB). Sieving of the soluble tumor macromolecules through long gel columns yielded molecular size distributions containing at least 7 sizes. Six tumor pools gave remarkably similar profiles, which were then compared with those previously obtained from normal, control, and preneoplastic livers of rats fed 3′-Me-DAB or N-2-fluorenylacetamide (2-acetyl-aminofluorene). In contrast to segregation of the soluble macromolecules of all these livers into fairly discrete and ordered size classes, the macromolecules of the primary liver tumors were distributed in markedly diffuse profiles. Among other differences, the relative amount of 15–20S macromolecules in the tumor extracts was double that in the liver extracts, while that of 6–7.5S macromolecules was half. A multitude of cellular proteins changed in amount as a result of the overall transformation of liver cells to overt tumors.